Pyrazolo-triazolo-pyrimidine derivatives as adenosine receptor antagonists: A possible template for adenosine receptor subtypes?

被引:35
作者
Baraldi, PG
Cacciari, B
Borea, PA
Varani, K
Pastorin, G
Da Ros, T
Tabrizi, MA
Fruttarolo, F
Spalluto, G
机构
[1] Univ Ferrara, Dipartimento Sci Farmaceut, I-44100 Ferrara, Italy
[2] Univ Ferrara, Sez Farmacol, Dipartimento Med Clin & Sperimentale, I-44100 Ferrara, Italy
[3] Univ Trieste, Dipartimento Sci Farmaceut, I-34127 Trieste, Italy
关键词
D O I
10.2174/1381612023392838
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Adenosine, a widely distributed modulator, regulates many physiological functions through specific cell membrane G-protein-coupled receptors classified as A(1), A(2A), A(2B) and A(3). An intense medicinal chemistry effort made over the last 20 years has led to a variety of selective adenosine receptor agonists and antagonists. In particular, the pyrazolo-triazolo-pyrimidine nucleus has been strongly investigated in the last years by our group. All the modifications performed and a tentative of structure-activity-relationship is reported. In fact, the combination of different substitutions at the N-7, N-8 and N-5 positions afford compounds which showed good affinity and selectivity for the different adenosine receptor subtypes. The data herein summarized, permit to speculate on the use of this nucleus as possible template for the adenosine receptor subtypes.
引用
收藏
页码:2299 / 2332
页数:34
相关论文
共 209 条
[1]   Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative disease [J].
Abbracchio, MP ;
Cattabeni, F .
NEUROPROTECTIVE AGENTS: FOURTH INTERNATIONAL CONFERENCE, 1999, 890 :79-92
[2]   The A3 adenosine receptor mediates cell spreading, reorganization of actin cytoskeleton, and distribution of Bcl-xL:: Studies in human astroglioma cells [J].
Abbracchio, MP ;
Rainaldi, G ;
Giammarioli, AM ;
Ceruti, S ;
Brambilla, R ;
Cattabeni, F ;
Barbieri, D ;
Franceschi, C ;
Jacobson, KA ;
Malorni, W .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 241 (02) :297-304
[3]  
Ali H, 1996, J PHARMACOL EXP THER, V276, P837
[4]   BRADYKININ INHIBITS CYCLIC-AMP ACCUMULATION IN D384-HUMAN ASTROCYTOMA-CELLS VIA A CALCIUM-DEPENDENT INHIBITION OF ADENYLYL CYCLASE [J].
ALTIOK, N ;
FREDHOLM, BB .
CELLULAR SIGNALLING, 1993, 5 (03) :279-288
[5]   ADENOSINE RECEPTOR-INDUCED CAMP CHANGES IN D384 ASTROCYTOMA-CELLS AND THE EFFECT OF BRADYKININ THEREON [J].
ALTIOK, N ;
BALMFORTH, AJ ;
FREDHOLM, BB .
ACTA PHYSIOLOGICA SCANDINAVICA, 1992, 144 (01) :55-63
[6]   Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist [J].
Aoyama, S ;
Kase, H ;
Borrelli, E .
JOURNAL OF NEUROSCIENCE, 2000, 20 (15) :5848-5852
[7]  
Apasov SG, 1997, J IMMUNOL, V158, P5095
[8]   Signaling via A2A adenosine receptor in four PC12 cell clones [J].
Arslan, G ;
Kull, B ;
Fredholm, BB .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1999, 359 (01) :28-32
[9]  
ASKALAN R, 1994, J NEUROCHEM, V63, P1477
[10]  
Auchampach JA, 1997, CIRC RES, V80, P800